AbbVie (ABBV) Company Description: AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and ...
BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline ... BeiGene may lose the lawsuit to AbbVie over Brukinsa and start to pay royalties, which lowers our ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...
More than 200 employees of 23andMe are being laid off as part of the company’s ongoing cost-cutting measures. The layoffs ...
19h
Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes -- Positive Topline Results ...
86% of respondents to a recent Veeva survey of pharma and biotech professionals said they are creating a greater volume of content now, compared to six months ago. Yet while many pharma ...
The Medicines and Healthcare products Regulatory Agency (MHRA) looks like it will once again be responsible for regulating drugs across the whole of the UK, in the wake of the government’s ...
Investor's Business Daily on MSN19h
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter BeatAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.
BioNTech is buying into one of the hottest areas of oncology, agreeing to pay $800 million to acquire China-based Biotheus ...
The global biopharmaceutical contract manufacturing market is set for substantial growth, with a projected Compound Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback